Common use of CLINICAL INFORMATION Clause in Contracts

CLINICAL INFORMATION. i. Prescribed indications • Treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment) • Treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours. ii. Dose & Route of administration Lanreotide should be used as the 1st line treatment. Octreotide is reserved for use if Lanreotide has been stopped due to adverse effects or lack of efficacy. Administration Lanreotide should be injected via the deep sub-cutaneous route in the superior external quadrant of the buttock. The skin should not be folded. The needle should be inserted rapidly to its full length, perpendicularly to the skin. Octreotide is administered by either subcutaneous injection or depot (deep intragluteal) IM injection.